Pearce IP BioBlast: w/e 31 July 2020

Significant biosimilar activities this week include:

  • 27 Jul 20, EU: Celltrion announced the European Commission has granted marketing authorisation for Remsima® (biosimilar infliximab) subcutaneous formulation for the treatment of adult patients with ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis.
     

  • 27 Jul 20: the Centre for Biosimilars reported a study presented at the American Academy of Dermatology's Virtual Meeting Experience 2020 which demonstrated  the safety, efficacy and immunogenicity of Boehringer Ingelheim's Cyltezo® (biosimilar adalimumab) is comparable to AbbVie's Humira®.
     

  • 28 Jul 20: Pfizer released its Q2 FY20  financial results.  Pfizer reported a 16% decrease in international revenues for Enbrel® (etanercept), attributing this decrease to biosimilar competition in Europe, Japan and Brazil.  Pfizer also revealed that it plans to launch Nyvepria® (biosimilar pegfilgrastim) in the US later this year.
     

  • 8 Jul 20: Amgen released its Q2 FY20 financial results.  Amgen reported the following impact to biologics/biosimilars global sales:

    • 6% year-over-year decrease for Prolia® (denosumab)

    • 9% year-over-year decrease for Enbrel® (etanercept)

    • 28% quarter-over-quarter decrease for Amgevita® (biosimilar adalimumab)

    • 28% year-over-year decrease for Neulasta (pegfilgrastim)

    • 35% year-over-year decrease for Neupogen® (filgrastim

    • 28% year-over-year decrease for Epogen® (epoetin alfa

    • 11% decrease year-over-year for Aranesp® (darbepoetin alfa)
      These decreases were attributed to a range of factors including competition, COVID-19 impacts and lower net selling prices.
       

  • 29 Jul 20, EU: Shanghai Henlius Biotech and Accord Healthcare jointly announced the European Commission has approved Zercepac® (biosimilar trastuzumab) for the treatment of HER2-positive early breast cancer, HER2-positive metastatic breast cancer and HER2-positive metastatic gastric cancer. 
     

  • 30 Jul 20, IN: Cadila Pharmaceuticals announced it has launched Ritucad® (biosimilar rituximab).  Ritucad® has been approved for Non-Hodgkin's Lymphoma and rheumatoid arthritis.  This follows Cadila's launch of Bevaro® (biosimilar bevacizumab) in India last week.
     

  • 30 Jul 20, US: Janssen announced the FDA approved an additional indication for Stelara® (ustekinumab) for paediatric patients with skin lesions or moderate to severe plaque psoriasis.

Share on Facebook
Share on Twitter
Please reload

Biosimilars Bulletin 

August 19, 2020

Please reload

Search by tags